AU2003250821A1

AU2003250821A1 - Fluorinated cycloalkyl-derivatised benzoylguanidines and their use as a medicament

Info

Publication number: AU2003250821A1
Application number: AU2003250821A
Authority: AU
Inventors: Heinz-Werner Kleemann
Original assignee: Aventis Pharma Deutschland GmbH
Current assignee: Sanofi Aventis Deutschland GmbH
Priority date: 2002-06-13
Filing date: 2003-06-02
Publication date: 2003-12-31
Anticipated expiration: 2023-06-02
Also published as: PT1515947E; MY130810A; RU2005100508A; WO2003106410A1; ES2333216T3; JP2005529182A; JP4383343B2; HRP20041175A2; CN1295213C; AU2003250821B2; MXPA04011361A; NO20050078L; RS105904A; EP1515947A1; CA2489245A1; ZA200409418B; PL372054A1; MA27234A1; MXPA04012231A; AR040201A1

Description

IN THE MATTER OF an Australian Application corresponding to PCT Application PCT/EP03/05738 I, Alan John SPARROW, translator to RWS Group plc, of Europa House, Marsham Way, Gerrards Cross, Buckinghamshire, England, do solemnly and sincerely declare that I am conversant with the English and German languages and am a competent translator thereof, and that to the best of my knowledge and belief the following is a true and correct translation of the PCT Application filed under No. PCT/EP03/05738. Date: 16 April 2004 A. J. SPARROW For and on behalf of RWS Group plc WO 03/106410 PCT/EP03/05738 FLUORINATED CYCLOALKYL-DERIVATIZED BENZOYLGUANIDINES AND THEIR USE AS A MEDICAMENT Fluorinated cycloalkyl-derivatized benzoylguanidines, process for their 5 preparation, their use as a medicament, and medicament containing them. The invention relates to compounds of the formula I H2)p ( 2)q ( F 2 )n ( H 2 )r

H

2 )m R5 R2 (I) X R1 R3 N NH 2 R4 0

NH

2 10 in which the meanings are: X oxygen, sulfur or NR6; R6 hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms or (CH2)k-CF3; k 0, 1, 2 or 3; 15 m zero, 1, 2 or 3; n zero, 1, 2 or 3; p zero, 1, 2, or 3; q 1, 2 or 3; r zero, 1, 2 or 3; 20 where the total of m, n, p, q and r is at least 2; R1 hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, CI, -OR(7), -NR(8)R(9) or -CsF 2 s+ 1 ; R(7), R(8) and R(9) independently of one another hydrogen, alkyl having 1, 2 or 3 25 carbon atoms or (CH2)t-CF3; s 1, 2, 3 or 4; t 0, 1, 2, 3 or 4; R2 hydrogen, F, Cl, alkyl having 1, 2, 3 or 4 carbon atoms or CF 3 ; R3 hydrogen, F, Cl, alkyl having 1, 2, 3 or 4 carbon atoms, CF 3 or 30 SOuR10; 2 u zero, 1 or 2; R10 alkyl having 1, 2, 3 or 4 carbon atoms or NR11R12; R1 1 and R12 independently of one another hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; 5 R4 hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(1 3), -NR(1 4)R(1 5) or -CvF2v+1; R(13), R(14) and R(15) independently of one another hydrogen, alkyl having 1, 2 or 3 carbon atoms or (CH2)W-CF 3 ; 10 v 1,2,3 or4; w 0, 1, 2, 3, or 4; R5 hydrogen or F; and the pharmacologically acceptable salts thereof. 15 Preference is given to compounds of the formula I in which the meanings are: X oxygen, sulfur or NR6; R6 hydrogen, methyl or CH 2

-CF

3 ; m zero, 1 or 2; 20 n zero, 1 or 2; p zero, 1 or 2; q 1 or 2; r zero, 1 or 2; where the total of m, n, p, q and r is at least 2; 25 R1 hydrogen, methyl, F, Cl, -OR(7), -NR(8)R(9) or -CF 3 ; R(7), R(8) and R(9) independently of one another hydrogen, methyl, CF 3 or CH 2

-CF

3 ; R2 hydrogen, F, Cl, methyl or CF 3 ; R3 hydrogen, F, Cl, alkyl having 1, 2, 3 or 4 carbon atoms, CF 3 , 30

SO

2

CH

3 or SO 2

NH

2 ; R4 hydrogen, methyl, F, Cl, -OR(13), -NR(14)R(15) or -CF 3 ; R(13), R(14) and R(15) independently of one another hydrogen, methyl, CF 3 or CH 2

-CF

3 ; R5 hydrogen or F; 35 and the pharmacologically acceptable salts thereof. Particular preference is given to compounds of the formula I in which the meanings are: X oxygen, sulfur or NR6; 3 R6 hydrogen, methyl or CH 2

-CF

3 ; m zero or 1; n zero, 1 or 2; p zero or 1; 5 q 1 or 2; r zero or 1; where the total of m, n, p, q and r is at least 2; R1 hydrogen, methyl, F, Cl, -OR(7), -NR(8)R(9) or -CF3; R(7), methyl, CF3 or CH2-CF3; 10 R(8) and R(9) independently of one another hydrogen, methyl or CH 2

-CF

3 ; R2 hydrogen, F or Cl; R3 CF3, SO 2

CH

3 or SO2NH2; R4 hydrogen; 15 R5 hydrogen or F; and the pharmacologically acceptable salts thereof. Very particular preference is given to the following compounds of the formula I, selected from the group: 20 N-[4-(3,3-difluorocyclobutoxy)-5-methanesulfonyl-2-methylbenzoyl] quanidine, N-[4-(3,3-difluorocyclobutylamino)-5-methanesulfonyl-2-methylbenzoyl] quanidine, N-{4-[(3,3-difluorocyclobutyl)methylamino]-5-methanesulfonyl-2-methyl 25 benzoyl}guanidine and N-{4-[(3,3-difluorocyclobutyl)methylamino]-5-ethanesulfonyl-2-methyl benzoyl}guanidine and the pharmaceutically acceptable salts thereof. 30 The compounds of the formula I, for example the substituents R1 to R4, contain one or more syntheses of asymmetry and they may thus be, independently of one another, of the S or R configuration. The compounds may exist as optical isomers, as diasteriomers, as racemates or as 35 mixtures thereof. The present invention encompasses all tautomeric forms of the compounds of the formula I and II.

4 Alkyl radicals may be straight-chain or branched. This also applies if they have substituents or occur as substituents of other radicals, for example in fluoroalkyl radicals or alkoxy radicals. Examples of alkyl radicals are methyl, ethyl, n-propyl, isopropyl (= 1-methylethyl), n-butyl, isobutyl 5 (= 2-methylpropyl), sec-butyl (= 1 -methylproyl) and tert-butyl (= 1 ,1-dimethylethyl). Preferred alkyl radicals are methyl, ethyl, n-propyl and isopropyl. One or more, for example 1, 2, 3, 4 or 5, hydrogen atoms in alkyl radicals may be replaced by fluorine atoms. Examples of such fluoroalkyl radicals are trifluoromethyl, 2,2,2-trifluoroethyl and 10 pentafluoroethyl. Substituted alkyl radicals may be substituted in any positions. Preferred compounds of the formula I are those in which the total of m, n, o, p, q and r is from 2 to 6. 15 The invention additionally relates to a process for preparing a compound of the formula 1, which comprises reacting a compound of the formula II

'H

2 )P ( 2)q F2) .F2)n

H

2 )r

H

2 )m R5 R2 (II) X R1 R3 / L R4 0 20 in which R(1) to R(5) and m to r have the stated meaning, and L is a leaving group which can easily undergo nucleophilic substitution, with guanidine. 25 The activated acid derivatives of the formula Il in which L is an alkoxy, preferably a methoxy, group, a phenoxy group, phenylthio, methylthio, 2-pyridylthio group, a nitrogen heterocycle, preferably 1-imidazolyl, are advantageously obtained in a manner known to the skilled worker from the underlying carbonyl chlorides (formula 11, L = Cl), which in turn can 5 themselves be prepared in a manner known to the skilled worker from the underlying carboxylic acids (formula 11; L = OH), for example using thionyl chloride. 5 Besides the carbonyl chlorides of the formula II (L = Cl) it is also possible to prepare other activated acid derivatives of the formula 11 in a manner known per se directly from the underlying benzoic acids (formula 11; L = OH), such as the methyl esters of the formula 11 with L = OCH 3 by treatment with gaseous HCI in methanol, the imidazolides of the formula 11 by treatment 10 with carbonyldiimidazole [L = 1 -imidazolyl, Staab, Angew. Chem. Int. Ed. Engl. 1, 351 - 367 (1962)], the mixed anhydrides with CI-COOC 2

H

5 or tosyl chloride in the presence of triethylamine in an inert solvent, as activations of benzoic acids with dicyclohexylcarbodiimide (DCC) or with O-[(cyano(ethoxycarbonyl)methylene)amino]-1,1,3,3-tetramethyluronium 15 tetrafluoroborate ('TOTU") [Proceedings of the 21. European Peptide Symposium, Peptides 1990, Editors E. Giralt and D. Andreu, Escom, Leiden, 1991] are possible. A number of suitable methods for preparing activated carboxylic acid derivatives of the formula 11 are indicated in J. March, Advanced Organic Chemistry, third edition (John Wiley & Sons, 20 1985), page 350, indicating source literature. Reaction of an activated carboxylic acid derivative of the formula 11 with guanidine takes place in a manner known to the skilled worker in a protic or aprotic polar but inert organic solvent. Those which have proved suitable 25 for the reaction of the methyl benzoates (II; L = OCH 3 ) with guanidine are methanol, isopropanol or THF at temperatures from 20 0 C to the boiling point of these solvents. Most reactions of compounds II with salt-free guanidine have advantageously been carried out in aprotic inert solvents such as THF, dimethoxyethane, dioxane or DMF. However, it is also 30 possible to use water in the presence of a base such as, for example, NaOH as solvent in the reaction of 11 with guanidine. If L is Cl, it is advantageous to add an acid scavenger, for example in the form of excess guanidine, to bind the hydrohalic acid. 35 The carboxylic acid derivatives of the formula 11 can be prepared from compounds of the formula 111. Some of the underlying benzoic acid derivatives of the formula Ill are known and described in the literature. The unknown compounds of the formula III can be prepared by methods known 6 from the literature. R2 L' R1 (III) R3 /M e, Et R4 0 5 The introduction of the fluorocycloalkyl nucleophiles into the 4 position takes place by nucleophilic aromatic substitution. Suitably protected benzoic acid derivatives of the formula 111, such as, for example, the methyl or ethyl esters, are employed in this case. L' is a leaving group which can easily be replaced by nucleophilic aromatic substitution, such as F, Cl, Br, I 10 or O-SO 2

CF

3 . The benzoic acid derivatives of the formula II obtained are then reacted by one of the process variants described above to give compounds of the formula I of the invention. 15 Benzoylguanidines of the formula I are generally weak bases and are able to bind acid to form salts. Suitable acid addition salts are salts of all pharmacologically acceptable acids, for example halides, in particular hydrochlorides, lactates, sulfates, citrates, tartrates, acetates, phosphates, 20 methylsulfonates, p-toluenesulfonates. The compounds of the formula I are substituted acylguanidines and inhibit the cellular sodium-proton antiporter (Na+/H+-exchanger, NHE). 25 The compounds of the invention, of the formula I, are distinguished by having unusually favorable ADME (absorption distribution metabolism excretion) properties compared with known benzoylguanidines, together with excellent activity in the inhibition of NA+/H+ exchange; these advantageous properties are dependent on the fluorinated cycloalkyl group. 30 In contrast to known acylguanidines, the compounds described herein show no unwanted and disadvantageous saluretic properties. Because of the NHE-inhibitory properties, the compounds of the formula I 7 and/or 11 and/or the pharmaceutically acceptable salts thereof are suitable for the prevention and treatment of diseases caused by activation or activated NHE, and of diseases caused secondarily by the NHE-related damage. 5 Since NHE inhibitors predominantly act via their effect on cellular pH regulation, they can generally be combined beneficially with other compounds which regulate the intracellular pH, with suitable combination partners being inhibitors of the carbonic anhydrase enzyme group, 10 inhibitors of systems transporting bicarbonate ions, such as of the sodium bicarbonate cotransporter (NBC) or of the sodium-dependent chloride bicarbonate exchanger (NCBE), and NHE inhibitors with inhibitory effect on other NHE subtypes, because it is possible through them to enhance or modulate the pharmacologically relevant pH-regulating effects of the NHE 15 inhibitors described herein. The use of the compounds of the invention relates to the prevention and treatment of acute and chronic diseases in veterinary and human medicine. 20 Thus, the NHE inhibitors of the invention are suitable for the treatment of diseases caused by ischemia and by reperfusion. The compounds described herein are suitable because of their pharmacological properties as antiarrhythmic medicaments. 25 Owing to their cardioprotective component, the NHE inhibitors of the formula I and/or 1I and/or the pharmaceutically acceptable salts thereof are outstandingly suitable for infarction prophylaxis and infarction treatment and for the treatment of angina pectoris, in which cases they also preventively inhibit or greatly reduce the pathophysiological processes 30 associated with the development of ischemia-induced damage, in particular in the triggering of ischemia-induced cardiac arrhythmias. Because of their protective effects against pathological hypoxic and ischemic situations, the compounds of the formula I and/or 11 and/or the pharmaceutically acceptable salts thereof used according to the invention can, because of 35 inhibition of the cellular Na+/H+ exchange mechanism, be used as medicaments for the treatment of all acute or chronic ischemia-induced damage or diseases induced primarily or secondarily thereby. This also relates to their use as medicaments for surgical interventions.

8 Thus, the compounds can be used during organ transplantations, it being possible to use the compounds both to protect the organs in the donor before and during the removal, to protect removed organs for example during treatment with or storage thereof in physiological bath liquids, and 5 during transference to the recipient organism. The compounds of the invention are likewise valuable medicaments with a protective effect when performing angioplastic surgical interventions, for example on the heart as well as on peripheral organs and vessels. 10 It has emerged that the compounds of the invention are exceptionally effective medicaments for life-threatening arrhythmias. Ventricular fibrillation is terminated and the physiological sinus rhythm of the heart is restored. 15 Since NHE1 inhibitors of human tissue and organs, especially the heart, protect effectively not only against damage caused by ischemia and reperfusion but also against the cytotoxic effect of medicaments like those used in particular in cancer therapy and the therapy of autoimmune 20 diseases, combined administration with compounds of the formula I and/or 11 and/or the pharmaceutically acceptable salts thereof is suitable for inhibiting the cytotoxic, especially cardiotoxic, side effects of said compounds. The reduction in the cytotoxic effects, especially the cardiotoxicity, resulting from comedication with NHE1 inhibitors makes it 25 additionally possible to increase the dose of the cytotoxic therapeutic agents and/or to prolong the medication with such medicaments. The therapeutic benefits of such a cytotoxic therapy can be considerably increased by combination with NHE inhibitors. 30 In addition, the NHE1 inhibitors of the invention of the formula I and/or 11 and/or the pharmaceutically acceptable salts thereof can be used when there is heart-damaging overproduction of thyroid hormones, thyrotoxicosis, or on external supply of thyroid hormones. The compounds of the formula I and/or II and/or the pharmaceutically acceptable salts 35 thereof are thus suitable for improving therapy with cardiotoxic medicaments. In accordance with their protective effect against ischemia-induced damage, the compounds of the invention are also suitable as medicaments 9 for the treatment of ischemias of the nervous system, especially of the central nervous system, being suitable for example for the treatment of stroke or of cerebral edema. 5 The compounds of the formula I and/or the pharmaceutically acceptable salts thereof are also suitable for the therapy and prophylaxis of diseases and disorders induced by overexcitability of the central nervous system, in particular for the treatment of epileptic disorders, centrally induced clonic and tonic spasms, states of psychological depression, anxiety disorders 10 and psychoses. In these cases it is possible to use the NHE inhibitors described herein alone or in combination with other substances with antiepileptic activity or antipsychotic active ingredients, or carbonic anhydratase inhibitors, for example with acetazolamide, and with other inhibitors of NHE or of the sodium-dependent chloride-bicarbonate 15 exchanger (NCBE). The compounds used according to the invention of the formula I and/or the pharmaceutically acceptable salts thereof are additionally likewise suitable for the treatment of types of shock such as, for example, of allergic, 20 cardiogenic, hypovolemic and bacterial shock. The compounds of the formula I and/or the pharmaceutically acceptable salts thereof can likewise be used for the prevention and treatment of thrombotic disorders because they, as NHE inhibitors, are able to inhibit 25 platelet aggregation themselves. They are additionally able to inhibit or prevent the excessive release, occurring after ischemia and reperfusion, of mediators of inflammation and coagulation, especially of von Willebrand factor and of thrombogenic selectin proteins. It is thus possible to reduce and eliminate the pathogenic effect of significant thrombogenic factors. The 30 NHE inhibitors of the present invention can therefore be combined with other anticoagulant and/or thrombolytic active ingredients such as, for example, recombinant or natural tissue plasminogen activator, streptokinase, urokinase, acetylsalicylic acid, thrombin antagonists, factor Xa antagonists, medicinal substances with fibrinolytic activity, thromboxane 35 receptor antagonists, phosphodiesterase inhibitors, factor Vila antagonists, clopidogrel, ticolopidine etc. Combined use of the present NHE inhibitors with NCBE inhibitors and/or with inhibitors of carbonic anhydrase such as, for example, with acetazolamide, is particularly beneficial.

10 The compounds of the formula I and/or the pharmaceutically acceptable salts thereof used according to the invention are additionally distinguished by a strong inhibitory effect on the proliferation of cells, for example fibroblast cellular proliferation and the proliferation of smooth vascular 5 muscle cells. The compounds of the formula I and/or 11 and/or the pharmaceutically acceptable salts thereof are therefore suitable as valuable therapeutic agents for diseases in which cellular proliferation represents a primary or secondary cause, and can therefore be used as antiatherosclerotics, agents for chronic renal failure, cancers. 10 It was possible to show that cell migration is inhibited by the compounds of the invention. The compounds of the formula I and/or the pharmaceutically acceptable salts thereof are therefore suitable as valuable therapeutic agents for dieases in which cell migration represents a primary or 15 secondary cause, such as, for example, cancers with a pronounced tendency to metastasis. The compounds of the formula I and/or the pharmaceutically acceptable salts thereof are further distinguished by a retardation or prevention of 20 fibrotic disorders. They are thus suitable as excellent agents for the treatment of cardiac fibroses, and of pulmonary fibrosis, hepatic fibrosis, renal fibrosis and other fibrotic disorders. They can thus be used for the treatment of organ hypertrophies and hyperplasias, for example of the heart and the prostate. They are therefore 25 suitable for the prevention and treatment of heart failure (congestive heart failure = CHF) and for the treatment and prevention of prostate hyperplasia or prostate hypertrophy. Since there is significant elevation in NHE in essential hypertensives, the 30 compounds of the formula I and/or the pharmaceutically acceptable salts thereof are suitable for the prevention and treatment of high blood pressure and of cardiovascular disorders. In these cases they can be used alone or with a suitable combination and formulation partner for high blood pressure treatment and of cardiovascular 35 disorders. Thus, for example, one or more diuretics with a thiazide-like action, loop diuretics, aldosterone and pseudoaldosterone antagonists, such as hydrochlorothiazide, indapamide, polythiazide, furosemide, piretanide, torasemide, bumetanide, amiloride, triamterene, spironolactone or eplerone, can be combined. The NHE inhibitors of the present invention 11 can further be used in combination with calcium channel blockers such as verapamil, diltiazem, amlodipine or nifedipine, and with ACE inhibitors such as, for example, ramipril, enalapril, lisinopril, fosinopril or captopril. Further beneficial combination partners are also beta-blockers such as metoprolol, 5 albuterol etc., antagonists of the angiotensin receptor and its receptor subtypes such as losartan, irbesartan, valsartan, omapatrilat, gemopatrilat, endothelin antagonists, renin inhibitors, adenosine receptor agonists, inhibitors and activators of potassium channels such as glibenclamide, glimepiride, diazoxide, cromokalim, minoxidil and derivatives thereof, 10 activators of the mitochondrial ATP-sensitive potassium channel (mitoK(ATP) channel), inhibitors of Kv1.5 etc. It has emerged that NHE1 inhibitors of the formula I and/or the pharmaceutically acceptable salts thereof have a significant 15 antiinflammatory effect and can thus be used as antiinflammatory drugs. Inhibition of the release of mediators of inflammation is noteworthy in this connection. The compounds can thus be used alone or in combination with an antiinflammatory drug for the prevention or treatment of chronic and acute inflammatory disorders. Combination partners advantageously used 20 are steroidal and non-steroidal antiinflammatory drugs. The compounds of the invention can also be used for the treatment of disorders caused by protozoa, of malaria and of coccidiosis in poultry. It has additionally been found that compounds of the formula I and/or the 25 pharmaceutically acceptable salts thereof show a beneficial effect on serum lipoproteins. It is generally acknowledged that blood fat levels which are too high, called hyperlipoproteinemias, represent an essential risk factor for the development of arteriosclerotic vascular lesions, especially coronary heart disease. The reduction of elevated serum lipoproteins 30 therefore has exceptional importance for the prophylaxis and regression of atherosclerotic lesions. Besides the reduction in total serum cholesterol, it is particularly important to reduce the proportion of specific atherogenic lipid fractions of this total cholesterol, in particular of the low density lipoproteins (LDL) and of the very low density lipoproteins (VLDL), 35 because these lipid fractions represent an atherogenic risk factor. By contrast, a protective function against coronary heart disease is ascribed to the high density lipoproteins. Accordingly, hypolipidemics should be able to reduce not only total cholesterol but, in particular, the VLDL and LDL serum cholesterol fractions. It has now been found that NHE1 inhibitors show 12 valuable therapeutically utilizable properties in relation to influencing the serum lipid levels. Thus, they significantly reduce the elevated serum concentrations of LDL and VLDL as are to be observed, for example, due to increased dietary intake of a cholesterol- and lipid-rich diet or in cases of 5 pathological metabolic alterations, for example genetically related hyperlipidemias. They can therefore be used for the prophylaxis and regression of atherosclerotic lesions by eliminating a causal risk factor. Included herein are not only the primary hyperlipidemias but also certain secondary hyperlipidemias occurring, for example, in association with 10 diabetes. In addition, the compounds of the formula I and/or the pharmaceutically acceptable salts thereof lead to a marked reduction in the infarctions induced by metabolic abnormalities and, in particular, to a significant reduction in the induced infarct size and the severity thereof. 15 The compounds of the invention are therefore advantageously used for producing a medicament for the treatment of hypercholesterolemia; for producing a medicament for the prevention of atherogenesis; for producing a medicament for the prevention and treatment of atherosclerosis, for producing a medicament for the prevention and treatment of diseases 20 induced by elevated cholesterol levels, for producing a medicament for the prevention and treatment of diseases induced by endothelial dysfunction, for producing a medicament for the prevention and treatment of atherosclerosis-induced hypertension, for producing a medicament for the prevention and treatment of atherosclerosis-induced thromboses, for 25 producing a medicament for the prevention and treatment of hypercholesterolemia-induced and endothelial dysfunction-induced ischemic damage and post-ischemic reperfusion damage, for producing a medicament for the prevention and treatment of hypercholesterolemia induced and endothelial dysfunction-induced cardiac hypertrophies and 30 cardiomyopathies and of congestive heart failure (CHF), for producing a medicament for the prevention and treatment of hypercholesterolemia induced and endothelial dysfunction-induced coronary vasospasms and myocardial infarctions, for producing a medicament for the treatment of said disorders in combinations with hypotensive substances, preferably 35 with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists. A combination of an NHE inhibitor of the formula I and/or the pharmaceutically acceptable salts thereof with an active ingredient lowering the blood fat levels, preferably with an HMG-CoA reductase inhibitor (for example lovastatin or pravastatin), the latter 13 bringing about a hypolipidemic effect and thus increasing the hypolipidemic properties of the NHE inhibitor of the formula I and/or the pharmaceutically acceptable salts thereof proves to be a favorable combination with enhanced effect and reduced use of active ingredients. 5 Thus, compounds of the formula I and/or the pharmaceutically acceptable salts thereof lead to effective protection against endothelial damage of various origins. This protection of the vessels against the syndrome of endothelial dysfunction means that the compounds of the formula I and/or 10 the pharmaceutically acceptable salts thereof are valuable medicaments for the prevention and treatment of coronary vasospasms, peripheral vascular diseases, in particular of intermittent claudication, atherogenesis and atherosclerosis, left ventricular hypertrophy and dilated cardiomyopathy and thrombotic disorders. 15 It has additionally been found that benzoylguanidine of the formula I and/or the pharmaceutically acceptable salts thereof are suitable in the treatment of non-insulin-dependent diabetes (NIDDM), in which case insulin resistance is repressed. It may in this connection be beneficial, to enhance 20 antidiabetic activity and type of effect, for the compounds of the invention to be combined with a biguanide such as metformin, with an antidiabetic sulfonylurea such as glyburide, glimepiride, tolbutamide etc., with a glucosidase inhibitor, with a PPAR agonist such as rosiglitazone, pioglitazone etc., with an insulin product in a different administration form, 25 with a DB4 inhibitor, with an insulin sensitizer or with meglitinide. Besides the acute antidiabetic effects, the compounds of the formula I and/or the pharmaceutically acceptable salts thereof counteract the development of late complications of diabetes and can therefore be used 30 as medicaments for the prevention and treatment of late damage from diabetes such as diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy and other disorders arising as a result of diabetes. In this connection they can be combined advantageously with the antidiabetic medicaments thus described under NIDDM treatment. 35 Combination with a favorable dosage form of insulin could be particularly important in this connection. The NHE inhibitors of the invention, of the formula 1, and/or the pharmaceutically acceptable salts thereof show, besides the protective 14 effects against acute ischemic events and the subsequent reperfusion events which are equally acutely stressing, also direct therapeutically utilizable effects on disorders and impairments of the entire mammalian organism which are connected with manifestations of the chronically 5 progressing aging process and which are independent of acute hypoperfusion states and occur under normal, nonischemic conditions. These pathological age-related manifestations induced over the long time of aging, such as disease, illness and death, which can now be treated with NHE inhibitors, comprise disorders and impairments which are crucially 10 caused by age-related changes in vital organs and their function, and become increasingly important in the aging organism. Examples of disorders connected with an age-related functional impairment, with age-related signs of wear of organs, are inadequate responsiveness and reactivity of the blood vessels in relation to contraction 15 and relaxation reactions. This age-related decline in vascular reactivity to constricting and relaxing stimuli, which are an essential process in the cardiovascular system and thus of life and health, can be significantly diminished or abolished by NHE inhibitors. An important function and a measure of the maintenance of vascular reactivity is the blocking or slowing 20 of the age-related progression of endothelial dysfunction, which can be abolished highly significantly by NHE inhibitors. The compounds of the formula I and/or the pharmaceutically acceptable salts thereof are thus outstandingly suitable for the treatment and prevention of age-related progression of endothelial dysfunction, especially of intermittent 25 claudication. An example of another variable characterizing the aging process is the decrease in the contractility of the heart and the decrease in the adaptation of the heart to a required pumping performance of the heart. This reduced 30 efficiency of the heart resulting from the aging process is in most cases associated with a dysfunction of the heart which is caused inter alia by deposition of connective tissue in the cardiac tissue. This deposition of connective tissue is characterized by an increase in the weight of the heart, by an enlargement of the heart and by restricted function of the heart. It 35 was surprising that it was possible virtually completely to inhibit such an aging of the organ heart. The compounds of the formula I and/or the pharmaceutically acceptable salts thereof are thus outstandingly suitable for the treatment and prevention of heart failure, of congestive heart failure

(CHF).

15 Whereas preceding patents and patent applications have claimed the treatment of various types of cancers which have already occurred, it was now extremely surprising that not only the cancer which has already 5 occurred can be cured by inhibition of proliferation, but that the age-related frequency of the development of cancer can be prevented and highly significantly delayed by NHE inhibitors. A particularly noteworthy finding is that disorders occurring in an age-related manner in all organs, and not just certain types of cancer, are suppressed or occur with a highly significant 10 delay. The compounds of the formula I and/or the pharmaceutically acceptable salts thereof are thus outstandingly suitable for the treatment and, in particular, the prevention of age-related types of cancer. There is now found to be not only a delay, shifted highly significantly in time 15 and exceeding the statistical normal extent, in the occurrence of age related disorders of all investigated organs including the heart, vessels, liver etc., and a highly significant delay in age-related cancer. On the contrary, there is also, surprisingly, a prolongation of life to an extent which has not to date been achievable by any other group of medicaments or by 20 any natural products. This unique effect of NHE inhibitors also makes it possible, besides use of the active ingredients alone on humans and animals, for these NHE inhibitors to be combined with other active principles, measures, substances and natural products used in gerontology and based on a different mechanism of action. Such classes of active 25 ingredients used in gerontological therapy are: in particular vitamins and substances with antioxidant activity. Since there is a correlation between caloric loading or food intake and the aging process, combination with dietary measures is possible, for example with appetite suppressants. Consideration may likewise be given to combination with hypotensive 30 medicaments such as with ACE inhibitors, angiotensin receptor antagonists, diuretics, Ca+ 2 antagonists etc., or with metabolism normalizing medicaments such as cholesterol-lowering agents. The compounds of the formula I and/or the pharmaceutically acceptable salts thereof are thus outstandingly suitable for the prevention of age 35 related tissue changes and for prolonging life while maintaining a high quality of life. The compounds of the invention are effective inhibitors of the cellular sodium/proton antiporter (Na/H exchanger) which, in numerous disorders 16 (essential hypertension, artherosclerosis, diabetes etc.), is elevated also in cells which are easily amenable to measurements, such as, for example, in erythrocytes, platelets or leukocytes. The compounds used according to the invention are therefore suitable as excellent and simple scientific tools, 5 for example in their use as diagnostic aids for the determination and differentiation of particular types of hypertension, but also of atherosclerosis, of diabetes and of late complications of diabetes, of proliferative disorders etc. 10 Additionally claimed is a medicine for human, veterinary or phytoprotective use comprising an effective amount of one or more compounds of the formula I and/or the pharmaceutically acceptable salts thereof, together with pharmaceutically acceptable carriers and additives, alone or in combination with other pharmacological active ingredients or medicaments. 15 Medicaments comprising a compound I can moreover for example be administered orally, parenterally, intravenously, rectally, percutaneously or by inhalation, with the preferred administration being dependent on the particular appearance of the disorder. The compounds I can moreover be 20 used alone or together with pharmaceutical excipients, both in veterinary medicine and in human medicine. The medicaments generally contain active ingredients of the formula I and/or the pharmaceutically acceptable salts thereof in an amount of 0.01 mg to 1 g per dose unit. 25 Excipients suitable for the desired pharmaceutical formulation are familiar to the skilled worker on the basis of his expert knowledge. Besides solvents, gel formers, suppository bases, tablet excipients and other active ingredient carriers, it is possible to use, for example, antioxidants, dispersants, emulsifiers, antifoams, masking flavors, preservatives, 30 solubilizers or colors. For a form for oral use, the active compounds are mixed with the additives suitable for this purpose, such as carriers, stabilizers or inert diluents, and converted by conventional methods into suitable dosage forms such as 35 tablets, coated tablets, two-piece capsules, aqueous, alcoholic or oily solutions. Examples of inert carriers which can be used are gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, especially corn starch. Preparation can moreover take place both as dry and as wet granules. Examples of suitable oily carriers or solvents 17 are vegetable or animal oils such as sunflower oil or fish liver oil. For subcutaneous or intravenous administration, the active compounds are converted into a solution, suspension or emulsion, if desired with the 5 substances customary for this purpose, such as solubilizers, emulsifiers or other excipients. Examples of suitable solvents are: water, physiological saline or alcohols, for example ethanol, propanol, glycerol, as well as sugar solutions such as glucose or mannitol solutions, or else a mixture of the various solvents mentioned. 10 Suitable as pharmaceutical formulation for administration in the form of aerosols or sprays are, for example, solutions, suspensions or emulsions of the active ingredient of the formula I in a pharmaceutically acceptable solvent such as, in particular, ethanol or water, or a mixture of such 15 solvents. The formulation may if required also comprise other pharmaceutical excipients such as surfactants, emulsifiers and stabilizers, and a propellant gas. Such a preparation normally contains the active ingredient in a 20 concentration of about 0.1 to 10, in particular of about 0.3 to 3% by weight. The dosage of the active ingredient of the formula I to be administered and the frequency of administration depend on the potency and duration of action of the compounds used; also on the nature and severity of the 25 disorder to be treated, and on the sex, age, weight and individual response of the mammal to be treated. On average, the daily dose of a compound of the formula I for a patient weighing about 75 kg is at least 0.001 mg/kg, preferably 0.01 mg/kg, up to 30 a maximum of 10 mg/kg, preferably 1 mg/kg, of bodyweight. For acute episodes of the disorder, for example immediately after suffering a myocardial infarction, it may be necessary for the dosages also to be higher. Especially on i.v. use, for example for an infarct patient in an intensive care unit, up to 700 mg per day may be necessary. The daily 35 dose can be divided into several, for example up to 4, individual doses.

18 List of abbreviations: ADME absorption-distribution-metabolism-excretion CDI diimidazol-1-yl-methanone 5 DIP diisopropyl ether DMF N,N-dimethylformamide EA ethyl acetate (EtOAc) El electron impact eq. equivalent 10 ES electrospray ionization Et ethyl HEP n-heptane KOtBu potassium 2-methylpropan-2-olate Me methyl 15 MeOH methanol mp melting point NMP 1 -methylpyrrolidin-2-one MTB 2-methoxy-2-methyl propane RT room temperature 20 THF tetrahydrofuran Example 1: N-[4-(3,3-Difluorocyclobutoxy)-5-methanesulfonyl-2 methylbenzoyl]guanidine F F 0 H H N O N,H 25 H a) (3,3-Difluorocyclobutoxymethyl)benzene 20.0 g of 3-benzyloxycyclobutanone (Bull. Chem. Soc. Jpn. (1984), 57(6), 1637) were dissolved in 150 ml of CH 2 CI2, and a solution of 25.0 g of 30 [bis(2-methoxyethyl)amino]sulfur trifluoride in 30 ml of CH 2 CI2 was added dropwise at RT. After stirring at RT for 5 h, 12.0 g of diethylaminosulfur trifluoride were added. After stirring at RT for a further 20 h, the reaction 19 mixture was washed 3 times with 100 ml of water each time. It was dried over Na2SO 4 , and the solvent was removed in vacuo. Chromatography on silica gel with EA/HEP 3:1 and subsequent kugelrohr distillation afforded 27.6 g of a colorless oil. 5 b) 3,3-Difluorocyclobutanol 22.4 g of (3,3-difluorocyclobutoxymethyl)benzene are dissolved in 100 ml of diethyl ether, and 1.4 g of 10% Pd/C are added. Hydrogenation was carried out at RT under 20 bar of H 2 for 5 h. The catalyst was washed with 10 10 ml of diethyl ether, and the solution was distilled. 14.0 g of the product (boiling point 80 0 C) were obtained as a mixture with diethyl ether and toluene. This mixture was reacted without further purification. c) Methyl 4-(3,3-difluorocyclobutoxy)-5-methanesulfonyl-2-methylbenzoate 15 370 mg of methyl 4-fluoro-5-methanesulfonyl-2-methylbenzoate, 297 mg of 3,3-difluorocyclobutanol and 1.47 g of Cs 2

CO

3 were dissolved in 10 ml of anhydrous NMP and stirred at 60 0 C for 4 h. The reaction mixture was then diluted with 125 ml of a 50% concentrated aqueous NaHCO 3 solution and 20 extracted 3 times with 100 ml of EA each time. It was dried over Na2SO4, and the solvent was removed in vacuo. Chromatography on silica gel with DIP resulted in 380 mg of a colorless oil. Rf (DIP) = 0.21 MS (DCI): 335 25 d) N-[4-(3,3-Difluorocyclobutoxy)-5-methanesulfonyl-2-methylbenzoyl] guanidine 566 mg of guanidinium chloride were dissolved in 5 ml of anhydrous DMF and added to a solution of 604 mg of KOtBu in 5 ml of anhydrous DMF. 30 This solution of guanidine in DMF prepared in this way was added to a solution of 360 mg of methyl 4-(3,3-difluorocyclobutoxy)-5 methanesulfonyl-2-methylbenzoate in 5 ml of DMF and stirred at RT for 24 h. The reaction mixture was diluted with 125 ml of a 50% concentrated aqueous NaHCO 3 solution and extracted 3 times with 80 ml of EA each 35 time. It was dried over Na 2

SO

4 , and the solvent was removed in vacuo. Chromatography on silica gel with EA/MeOH 5:1 afforded 175 mg of colorless crystals, mp 273 0 C (with decomposition). Rf (EA/MeOH 5:1) = 0.50 MS (ES+): 362 20 Example 2 N-[4-(3,3-Difluorocyclobutylamino)-5-methanesulfonyl-2-methylbenzoyl] guanidine F F HN O0, /0 o S\ N - , , N H 2 5

NH

2 a) 3,3-Difluorocyclobutylamine, hydrochloride 16.7 g of 3,3-difluorocyclobutanecarboxylic acid (J. Org. Chem.. 1987, 52, 1872) were dissolved in 180 ml of CHCl 3 , and 36 ml of H 2

SO

4 (98%) were 10 added. The mixture was heated to 500C and, at this temperature, 16 g of NaN 3 were added in portions over the course of 45 minutes. The mixture was stirred at 500C for 2 h and then cooled to room temperature and finally poured onto 250 g of ice. Extraction 3 times with 100 ml of diethyl ether each time recovered 0.7 g of unreacted 3,3-difluorocyclobutanecarboxylic 15 acid. The aqueous phase was adjusted to pH = 12-13 with aqueous NaOH solution and extracted 3 times with 100 ml of CH 2 Cl 2 each time. The organic phase was washed with 100 ml of water, and then 130 ml of a 2N aqueous HCI solution were added and the volatile constituents were removed in vacuo. 15.3 g of a colorless solid were obtained, mp 315'C 20 (decomposition). b) N-(3,3-Difluorocyclobutyl)methanesulfonamide 0.60 g of 3,3-difluorocyclobutylamine, hydrochloride, were suspended in 40 ml of CH 2 Cl 2 and, at RT, 2.9 ml of triethylamine were added. This 25 resulted in a clear solution. Then, at RT, 1.0 ml of methanesulfonyl chloride was slowly added dropwise, and the reaction mixture was left to stand at this temperature for 16 h. The volatile constituents were then removed in vacuo, and the residue was taken up and partitioned with 200 ml of EA and 100 ml of a saturated aqueous Na 2

CO

3 solution. The organic phase was 30 subsequently washed twice with 20 ml of a saturated aqueous NaHSO 4 solution each time and twice with 30 ml of a saturated aqueous Na 2 CO3 21 solution each time. MgSO 4 was used for drying, and the solvent was removed in vacuo. 700 mg of a colorless resin were obtained. Rf (EA) = 0.28 MS (DCI): 186 5 c) Methyl 4-(3,3-difluorocyclobutylamino)-5-methanesulfonyl 2-methylbenzoate 0.70 g of N-(3,3-difluorocyclobutyl)methanesulfonamide, 0.93 g of methyl 4-fluoro-5-methanesulfonyl-2-methylbenzoate and 1.5 ml of N"-tert-butyl N,N,N',N'-tetramethylguanidine were dissolved in 10 ml of NMP 10 (anhydrous) and stirred at 1500C for 6 h. The reaction mixture was cooled to RT, diluted with 200 ml of EA and washed firstly 3 times with 20 ml of a saturated aqueous NaHSO 4 solution each time and then 3 times with 30 ml of a saturated aqueous Na 2

CO

3 solution each time. MgSO 4 was used for drying, and the solvent was removed in vacuo. Chromatography on silica 15 gel with DIP afforded 220 mg of a colorless foam. Rf (DIP) = 0.31 MS (ES*): 334 d) 4-(3,3-Difluorocyclobutylamino)-5-methanesulfonyl-2-methylbenzoic acid 210 mg of methyl 4-(3,3-difluorocyclobutylamino)-5-methanesulfonyl 20 2-methylbenzoate were dissolved in 10 ml of dioxane, and 0.47 ml of a 2N aqueous NaOH solution was added. The mixture was stirred at RT for 18 h and then the solvents were removed in vacuo. The residue was taken up in 10 ml of water, adjusted to pH = 2 with aqueous HCI solution and extracted 3 times with 20 ml of EA each time. MgSO 4 was used for drying, and the 25 solvent was removed in vacuo. 196 mg of an amorphous solid were obtained. Rf (EA) = 0.40 MS (ES-): 318 e) N-[4-(3,3-Difluorocyclobutylamino)-5-methanesufonyl-2-methylbenzoyl] 30 guanidine 40 mg of 4-(3,3-difluorocyclobutylamino)-5-methanesulfonyl 2-methylbenzoic acid were dissolved in 1 ml of DMF (anhydrous) and, at RT, 26 mg of CDI were added, and the mixture was stirred at RT for 6 h to result in the intermediate imidazolide. Alongside, 72 mg of guanidine 35 hydrochloride were stirred together with 70 mg of KOtBu in 1 ml of DMF (anhydrous) at RT for 30 minutes. This solution of the guanidine base was then added to the solution of the imidazolide, and the mixture was left to stand at RT for 18 h. It was then diluted with 50 ml of water and the pH was adjusted to pH = 8 with dilute aqueous HCI solution. Three extractions were 22 carried out with 10 ml of EA each time and, after drying over MgSO 4 , the solvent was removed in vacuo. 37 mg of an amorphous solid were obtained. Rf (EA/MeOH 10:1) = 0.12 MS (ES*): 360 5 The NHE-1 inhibition was determined as follows: FLIPR assay for determining NHE-1 inhibitors by measurement of the recovery in pHi in transfected cell lines which express human NHE-1 10 The assay is carried out in an FLIPR (fluorescent imaging plate reader) with black-walled 96-well microtiter plates with clear bases. The transfected cell lines expressing the various NHE subtypes (the parental cell line LAP-1 shows no endogenous NHE activity as a result of mutagenesis and 15 subsequent selection) are seeded the preceding day at a density of -25 000 cells/well. [The growth medium for the transfected cells (Iscove +10% fetal calf serum) additionally contains G418 as selection antibiotic in order to ensure the presence of the transfected sequences.] 20 The actual assay starts with the removal of the growth medium and addition of 100 ptl of loading buffer per well (5 pM BCECF-AM [2',7' bis(carboxyethyl)-5-(and -6)-carboxyfluorescein, acetoxymethyl ester] in 20 mM NH4CI, 115 mM choline chloride, 1 mM MgCl2, 1 mM CaCl2, 25 5 mM KCI, 20 mM HEPES, 5 mM glucose; pH 7.4 [adjusted with KOH]). The cells are then incubated at 370C for 20 minutes. This incubation leads to loading of the cells with the fluorescent dye whose fluorescence intensity depends on pHi, and with NH4CI which makes the cells slightly alkaline. [The nonfluorescent dye precursor BCECF-AM is, as ester, membrane 30 permeable. The actual dye BCECF which is not membrane-permeable is liberated inside cells by esterases.] After this incubation for 20 minutes, the loading buffer which contains

NH

4 CI and free BCECF-AM is removed by washing three times in a cell 35 washer (Tecan Columbus) with in each case 400 pl of washing buffer (133.8 mM choline chloride, 4.7 mM KCI, 1.25 mM MgCl2, 1.25 mM CaC2, 0.97 mM K 2

HPO

4 , 0.23 mM KH 2

PO

4 , 5 mM HEPES, 5 mM glucose; pH 7.4 [adjusted with KOH]). The residual volume remaining in the wells is 90 pl (50-125 pl possible). This washing step removes the free BCECF-AM 23 and results, as a consequence of the removal of the external NH4+ ions, in intracellular acidification (- pHi 6.3 - 6.4). Since the equilibrium of intracellular NH 4 + with NH 3 and H+ is disturbed by the removal of the extracellular NH 4 + and by the subsequent instantaneous 5 passage of the NH 3 through the cell membrane, the washing process results in H+ remaining inside the cells, which is the cause of the intracellular acidification. This may eventually lead to cell death if it persists long enough. It is important at this point that the washing buffer is sodium-free (<1 mM) 10 because extracellular sodium ions would lead to an instantaneous recovery of the pHi through the activity of the cloned NHE isoforms. It is likewise important for all the buffers used (loading buffer, washing buffer, recovery buffer) not to contain any HCO 3 ions, because the presence of bicarbonate would lead to activation of interfering bicarbonate 15 dependent pHi regulatory systems present in the parental LAP-1 cell line. The microtiter plates with the acidified cells are then (up to 20 minutes after the acidification) transferred to the FLIPR. In the FLIPR, the intracellular fluorescent dye is excited by light with a wavelength of 488 nm generated 20 by an argon laser, and the measured parameters (laser power, illumination time and aperture of the CCD camera incorporated in the FLIPR) are chosen so that the average fluorescence signal per well is between 30 000 and 35 000 relative fluorescence units. 25 The actual measurement in the FLIPR starts with a photograph being taken by the CCD camera every two seconds under software control. After ten seconds, the recovery of the intracellular pH is initiated by adding 90 p of recovery buffer (133.8 mM NaCl, 4.7 mM KCl, 1.25 mM MgCl2, 1.25 mM CaC12, 0.97 mM K2HPO 4 , 0.23 mM KH2PO 4 , 10 mM HEPES, 5 mM 30 glucose; pH 7.4 [adjusted with NaOH]) by means of the 96-well pipettor incorporated in the FLIPR. Positive control wells (100% NHE activity) are those to which pure recovery buffer is added, while negative controls (0% NHE activity) receive washing buffer. Recovery buffer with twice the concentration of test substance is 35 added to all the other wells. Measurement in the FLIPR terminates after 60 measurements (two minutes). The raw data are exported into the ActivityBase program. This program firstly calculates the NHE activities for each tested substance concentration 24 and, from these, the IC 50 values for the substances. Since the progress of pHi recovery is not linear throughout the experiment, but falls at the end owing to decreasing NHE activity at higher pHi values, it is important to select for evaluation of the measurement the part in which the increase in 5 fluorescence of the positive controls is linear. Example NHE1 inhibition IC50 [nM] 1 5.9

Claims

1. A fluorinated cycloalkyl-derivatized benzoylguanidine of the formula I H 2 )p ( 2)q ( F 2 )n1 ( H 2 )r H 2 )n R5 R2 (I) X R1 NNN R3 NYNH 2 5 R4 0 NH 2 in which the meanings are: X oxygen, sulfur or NR6; R6 hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms or (CH2)k-CF3; k 0, 1, 2 or 3; 10 m zero, 1, 2 or 3; n zero, 1, 2 or 3; p zero, 1, 2, or 3; q 1, 2 or 3; r zero, 1, 2 or 3; 15 where the total of m, n, p, q and r is at least

2; R1 hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(7), -NR(8)R(9) or -CsF2s+1; R(7), R(8) and R(9) independently of one another hydrogen, alkyl having 1, 2 or 3 carbon 20 atoms or (CH2)t-CF3; s 1,2,3or4; t 0, 1, 2, 3 or 4; R2 hydrogen, F, Cl, alkyl having 1, 2, 3 or 4 carbon atoms or CF 3 ; R3 hydrogen, F, Cl, alkyl having 1, 2, 3 or 4 carbon atoms, CF 3 or 25 SOuR10; u zero, 1 or 2; R10 alkyl having 1, 2, 3 or 4 carbon atoms or NR1 1 R12; R1 1 and R1 2 independently of one another hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; 30 R4 hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR(13), 26 -NR(14)R(15) or -CvF2v+1; R(13), R(14) and R(15) independently of one another hydrogen, alkyl having 1, 2 or 3 carbon atoms or (CH2)w-CF3; 5 v 1, 2, 3 or 4; w 0, 1, 2, 3, or 4; R5 hydrogen or F; and the pharmacologically acceptable salts thereof. 10 2. A compound of the formula I as claimed in claim 1, wherein the meanings are: X oxygen, sulfur or NR6; R6 hydrogen, methyl or CH 2 -CF 3 ; m zero, 1 or 2; 15 n zero, 1 or2; p zero, 1 or 2; q 1 or 2; r zero, 1 or 2; where the total of m, n, p, q and r is at least 2; 20 R1 hydrogen, methyl, F, Cl, -OR(7), -NR(8)R(9) or -CF 3 ; R(7), R(8) and R(9) independently of one another hydrogen, methyl, CF 3 or CH 2 -CF 3 ; R2 hydrogen, F, Cl, methyl or CF 3 ; R3 hydrogen, F, Cl, alkyl having 1, 2, 3 or 4 carbon atoms, CF3, 25 S02CH 3 or SO 2 NH 2 ; R4 hydrogen, methyl, F, Cl, -OR(13), -NR(14)R(15) or -CF3; R(13), R(14) and R(15) independently of one another hydrogen, methyl, CF 3 or CH 2 -CF 3 ; R5 hydrogen or F; 30 and the pharmacologically acceptable salts thereof.

3. A compound of the formula I as claimed in claim 1 or 2, wherein the meanings are: X oxygen, sulfur or NR6; 35 R6 hydrogen, methyl or CH 2 -CF 3 ; m zero or 1; n zero, 1 or 2; p zero or 1; q 1 or 2; 27 r zero or 1; where the total of m, n, p, q and r is at least 2; R1 hydrogen, methyl, F, Cl, -OR(7), -NR(8)R(9) or -CF 3 ; R(7), methyl, CF3 or CH 2 -CF 3 ; 5 R(8) and R(9) independently of one another hydrogen, methyl or CH2-CF 3 ; R2 hydrogen, F or Cl; R3 CF3, SO 2 CH 3 or SO 2 NH2; R4 hydrogen; 10 R5 hydrogen or F; and the pharmacologically acceptable salts thereof.

4. A compound of the formula I as claimed in one or more claims 1, 2 and 3, selected from the group: 15 N-[4-(3,3-difluorocyclobutoxy)-5-methanesulfonyl-2-methylbenzoyl] quanidine, N-[4(3,3-difluorocyclobutylamino)-5-methanesulfonyl-2-methylbenzoyl] quanidine, N-{4-[(3,3-difluorocyclobutyl)methylamino]-5-methanesufonyl-2-methyl 20 benzoyl}guanidine and N-{4-[(3,3-difluorocyclobutyl)methylamino]-5-ethanesulfonyl-2-methyl benzoyl}guanidine and the pharmaceutically acceptable salts thereof. 25

5. A compound of the formula I and/or the pharmaceutically acceptable salts thereof as claimed in one or more of claims 1 to 4 for use as medicament. 30

6. The use of a compound of the formula I and/or the pharmaceutically acceptable salts thereof as claimed in one or more of claims 1 to 4 for producing a medicament for the treatment or prophylaxis of acute or chronic damage, disorders or indirect sequelae of organs and tissues caused by ischemic events or by reperfusion events, for the treatment or 35 prophylaxis of arrhythmias, of life-threatening ventricular fibrillation of the heart, of myocardial infarction, of angina pectoris, for the treatment or prophylaxis of ischemic states of the heart, of ischemic states of the peripheral and central nervous system or of stroke or of ischemic states of peripheral organs and tissues, for the treatment or prophylaxis of states of 28 shock, or diseases in which cell proliferation represents a primary or secondary cause, of cancer, of metastasis, of prostate hypertrophy or of prostate hyperplasia, of atherosclerosis or of impairments of lipid metabolism, of high blood pressure, in particular of essential hypertension, 5 of disorders of the central nervous system, especially of disorders resulting through CNS overexcitability, such as epilepsy or centrally induced convulsions, of disorders of the central nervous system, especially of anxiety states, depressions or psychoses, for the treatment or prophylaxis of non-insulin-dependent diabetes mellitus (NIDDM) or late damage from 10 diabetes, of thromboses, or disorders resulting from endothelial dysfunction, of intermittent claudication, for the treatment or prophylaxis of fibrotic disorders of internal organs, fibrotic disorders of the liver, fibrotic disorders of the kidney, fibrotic disorders of vessels and fibrotic disorders of the heart, for the treatment or prophylaxis of heart failure or of congestive 15 heart failure, acute or chronic inflammatory disorders, of disorders caused by protozoa, of malaria and of coccidiosis in poultry and for use in surgical operations and organ transplantations, for preserving and storing transplants for surgical procedures, for preventing age-related tissue change, for producing a medicament directed against aging or for 20 prolonging life, for the treatment and reduction of the cardiotoxic effects in thyrotoxicosis or for producing a diagnostic aid.

7. The use of a compound of the formula I and/or the pharmaceutically acceptable salts thereof as claimed in one or more of claims 1 to 4 in 25 combination with other medicaments or active ingredients for producing a medicament for the treatment or prophylaxis of acute or chronic damage, disorders or indirect sequelae of organs and tissues caused by ischemic events or by reperfusion events, for the treatment or prophylaxis of arrhythmias, of life-threatening ventricular fibrillation of the heart, of 30 myocardial infarction, of angina pectoris, for the treatment or prophylaxis of ischemic states of the heart, of ischemic states of the peripheral and central nervous system or of stroke or of ischemic states of peripheral organs and tissues, for the treatment or prophylaxis of states of shock, of diseases in which cell proliferation represents a primary or secondary cause, of cancer, 35 of metastasis, of prostate hypertrophy or of prostate hyperplasia, of atherosclerosis or of impairments of lipid metabolism, of high blood pressure, in particular of essential hypertension, of disorders of the central nervous system, especially of disorders resulting through CNS overexcitability, such as epilepsy or centrally induced convulsions, of 29 disorders of the central nervous system, especially of anxiety states, depressions or psychoses, for the treatment or prophylaxis of non-insulin dependent diabetes mellitus (NIDDM) or late damage from diabetes, of thromboses, or disorders resulting from endothelial dysfunction, of 5 intermittent claudication, for the treatment or prophylaxis of fibrotic disorders of intemal organs, fibrotic disorders of the liver, fibrotic disorders of the kidney, fibrotic disorders of vessels and fibrotic disorders of the heart, for the treatment or prophylaxis of heart failure or of congestive heart failure, acute or chronic inflammatory disorders, of disorders caused by 10 protozoa, of malaria and of coccidiosis in poultry and for use in surgical operations and organ transplantations, for preserving and storing transplants for surgical procedures, for preventing age-related tissue change, for producing a medicament directed against aging or for prolonging life, for the treatment and reduction of the cardiotoxic effects in 15 thyrotoxicosis or for producing a diagnostic aid.

8. The use of a compound of the formula I and/or the pharmaceutically acceptable salts thereof as claimed in claim 7 in combination with cardiotoxic and cytotoxic medicaments or active ingredients for producing a 20 medicament with reduced cardiotoxic and cytotoxic properties.

9. The use of a compound of the formula I and/or its pharmaceutically acceptable salts, alone or in combination with other medicaments or active ingredients, as claimed in claim 6 and/or 7 for producing a medicament for 25 the treatment or prophylaxis of acute and chronic damage, disorders or indirect sequelae of organs and tissues caused by ischemic events or by reperfusion events.

10. The use of a compound of the formula I and/or the pharmaceutically 30 acceptable salts thereof alone or in combination with other medicaments or active ingredients as claimed in claim 6 and/or 7 for producing a medicament for the treatment of life-threatening ventricular fibrillation of the heart. 35

11. The use of a compound of the formula I and/or the pharmaceutically acceptable salts thereof alone or in combination with other medicaments or active ingredients as claimed in claim 6 and/or 7 for producing a medicament for the treatment of or prophylaxis of metastasis. 30

12. The use of a compound of the formula I and/or its pharmaceutically acceptable salts, alone or in combination with other medicaments or active ingredients, as claimed in claim 6 and/or 7 for producing a medicament for the treatment or prophylaxis of fibrotic heart diseases, of heart failure or of 5 congestive heart failure.

13. A medicine for human, veterinary and/or phytoprotective use comprising an effective amount of at least one compound of the formula I and/or the pharmaceutically acceptable salts as claimed in one or more of 10 claims 1 to 4, together with pharmaceutically acceptable carriers and additives.

14. A medicine for human, veterinary and/or phytoprotective use comprising an effective amount of at least one compound of the formula 1 15 and/or the pharmaceutically acceptable salts as claimed in one or more of claims 1 to 4, together with pharmaceutically acceptable carriers and additives in combination with other pharmacological active ingredients or medicaments.